Tenaya director granted 120,000 stock options

Tenaya Therapeutics director Deepak Srivastava received a grant of stock options for 120,000 shares of common stock at an exercise price of $0.7989 per share.

Rhea-AI Filing Summary

Tenaya Therapeutics director Deepak Srivastava received a grant of stock options for 120,000 shares of common stock at an exercise price of $0.7989 per share. The options vest in full on May 28, 2027, or earlier immediately before the next annual stockholder meeting, if he continues as a service provider. The options expire on May 27, 2036.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 1 txn

Insider Srivastava Deepak

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 120,000 contracts (Direct)

Footnotes (1)

1. F1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Key Figures

Option grant size: 120,000 shares Exercise price: $0.7989 per share Underlying shares: 120,000 shares +3 more

6 metrics

Option grant size 120,000 shares Stock Option (Right to buy) grant

Exercise price $0.7989 per share Conversion or exercise price for options

Underlying shares 120,000 shares Common stock underlying the options

Shares following transaction 120,000 options Total derivative securities held after grant

Vesting date May 28, 2027 Full vesting or earlier before next annual meeting

Expiration date May 27, 2036 Option term end date

Key Terms

Stock Option (Right to buy), Equity Incentive Plan, vesting, service provider

4 terms

Stock Option (Right to buy) financial

"security_title: "Stock Option (Right to buy)""

Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

service provider financial

"subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tenaya Therapeutics (TNYA) director Deepak Srivastava receive in this Form 4?

He received a grant of stock options for 120,000 shares of common stock. These options are part of Tenaya’s 2021 Equity Incentive Plan and represent compensation rather than an open-market share purchase.

What is the exercise price of Deepak Srivastava’s new Tenaya (TNYA) options?

The options have an exercise price of $0.7989 per share. This is the price at which he can buy Tenaya common stock once the options vest, regardless of the future market price.

When do Deepak Srivastava’s Tenaya (TNYA) stock options vest?

The options vest in full on May 28, 2027, or earlier immediately before the next annual meeting of stockholders after the grant date, if he continues as a service provider until that time.

When do the stock options granted to Deepak Srivastava expire at Tenaya (TNYA)?

The options expire on May 27, 2036. After this date, any unexercised portion of the 120,000-share option grant will no longer be exercisable by the reporting person.

Is Deepak Srivastava’s Tenaya (TNYA) Form 4 a market buy or sell?

No, it reports a grant of stock options, not an open-market trade. The transaction is coded as a grant or award (code A), reflecting equity compensation, with no shares bought or sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 07:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Srivastava Deepak

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027(1)	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)